Pentwater Capital Management 13F: Cuts RNA Stake by $73M

Pentwater Capital Management Scales Back Atrium Therapeutics Holdings

Pentwater Capital Management trimmed its investment in Atrium Therapeutics, Inc. (NASDAQ:RNA) significantly during the period ended May 15, 2026. A recent Form 13F filing submitted to the Securities and Exchange Commission shows that the fund cut its position by 90.0%, shedding 5,423,851 shares. Institutional filings like this one look backward and may not show where the fund stands today.

Trimming the Stake Down to 602,649 Shares

Before the reduction, Pentwater Capital Management held 6,026,500 shares of the biopharmaceutical company. After selling the vast majority of its stake, the fund finished the period with 602,649 shares. Based on the spot price around the filing, that remaining block carried a value of approximately $8.11 million.

Atrium Therapeutics Stock Performance and Valuation

Atrium Therapeutics shares trade on the NasdaqGS under the ticker RNA. The stock recently changed hands at $13.45. Because the company is not currently profitable, it has no meaningful P/E ratio to evaluate earnings against price. Investors tracking the wider picture should note that 13F filings are historic snapshots and do not necessarily reflect current portfolio adjustments.

Analysts Set New Price Targets

Wall Street firms continue following the biotech firm closely. HC Wainwright & Co. initiated coverage on the stock with a buy rating and a $25.00 price target on August 6, 2026. A few days later, on August 14, 2026, HC Wainwright & Co. reiterated its buy rating and kept its $25.00 price target intact. Across four analyst opinions, the mean price target stands at $25.00.

Inside Atrium Therapeutics and Its Pipeline

Atrium Therapeutics is a San Diego-based biopharmaceutical company focused on developing ribonucleic acid therapies for heart conditions. Its pipeline includes experimental treatments for genetic and cardiac diseases, such as PRKAG2 syndrome and PLN cardiomyopathy. The company also maintains research collaborations with major drugmakers like Bristol-Myers Squibb and Eli Lilly.

What to Watch Next for RNA

Market participants will look ahead to the company's next earnings report scheduled for November 9, 2026. Future regulatory updates on its drug candidates will also provide further insight into how institutional managers adjust their portfolios going forward.